Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Plays Up Potential First-In-Class Schizophrenia Drug In R&D Review

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche has launched an expansive Phase III program for the glycine reuptake inhibitor RG1678 for both positive and negative symptoms of the disease.

You may also be interested in...



Roche’s Breast Cancer Strategy Paying Off, But Diversification Difficult

Roche’s key HER2 breast cancer franchise boasted a stellar sales performance in the first-quarter – rising 27% in the U.S. alone – and the rest of the cancer business followed suit. But, the loss of schizophrenia candidate bitopertin casts a shadow on the firm’s plans for neuroscience.

Bitopertin’s Schizophrenia Failure Stirs Doubt About Roche’s CNS Plans

Roche’s bitopertin fails in the first two of six Phase III schizophrenia trials to report, raising questions about prospects for more diversity outside the company’s core strength in oncology.

Roche's CNS Drug Pipeline Matures: More Investment, More Promise

Roche Holding AG has established itself as a leader in areas like oncology, infectious disease, liver disease and inflammatory disease. Now, the company is eyeing the central nervous system as a new frontier for its R&D, stealthily building a considerable clinical-stage pipeline in the process.

Related Content

Topics

UsernamePublicRestriction

Register

PS071591

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel